Voided Urinary Cytology in Bladder Cancer: Is It Time to Review the Indications?

Urology

Volumn 70, Issue 2, 2007, Pages 267-271

  Talwar, Raghav ^a   Sinha, Tapan ^a   Karan, S C ^a   Doddamani, D ^a   Sandhu, A ^a   Sethi, G S ^a   Srivastava, A ^a   Narang, V ^a   Agarwal, A ^a   Adhlakha, N ^a  

^a ARMY HOSPITAL RESEARCH AND REFERRAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEAR MATRIX PROTEIN 22;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CYTODIAGNOSIS; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HEMATURIA; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN DETERMINATION; QUALITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; TUMOR BIOPSY; URINE CYTOLOGY;

ADULT; AGED; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS; URINE;

EID: 34548457800     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.03.070     Document Type: Article

References (29)

1. Karakiewicz P.I., Benayoun S., Zippe C., et al. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int 97 (2006) 997-1001
2. Murphy W.M., Soloway M.S., and Jukkola A.F. Urinary cytology and bladder cancer: the cellular features of transitional cell neoplasms. Cancer 53 (1984) 1555-1565
3. Cordon-Cardo C., Wartinger D.D., Melamed M.R., et al. Immunopathologic analysis of human urinary bladder cancer: characterization of two new antigens associated with low grade superficial bladder tumors. Am J Pathol 140 (1992) 375-380
4. Soloway M.S., Briggman J.V., Carpinto G.A., et al. Use of new tumor marker, urinary NMP22 in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 156 (1996) 363-367
5. Sarosody M.F., Vere White R.W., Soloway M.S., et al. Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol 154 (1995) 379-384
6. Parry W.L., and Hemstreet G.P. Cancer detection by quantitative fluorescence image analysis. J Urol 139 (1988) 270-274
7. Guirguis R., Schiffman E., Liu B., et al. Detection of autocrine motility factor in urine as a marker of bladder cancer. J Natl Cancer Inst 80 (1988) 1203-1208
8. Lance R.S., Aldous W.K., Blaser J., et al. Telomerase activity in solid transitional cell carcinoma (TCC) and bladder washings (abstract). J Urol 157 4 (1997) 338 supplement
9. Johnston B., Morales A., Emerson L., et al. Rapid detection of bladder cancer: a comparative study of point of care tests. J Urol 156 (1997) 2098-2101
10. Berezney R., and Coffey D.S. Identification of a nuclear matrix protein. Biochem Biophys Res Commun 60 (1974) 1410-1417
11. Fey E.G., Krochmalnic G., and Penman S. The non chromatic substructure of the nucleus: the ribonucleoprotein (RNP)-containing RNP depleted matrices analyzed by sequential fractionation and resin less section electron microscopy. J Cell Biol 102 (1986) 1654-1665
12. Kumara Siri M.H., Shaprio L.F., and Surks M.I. Association of the 3,5,3e trodo-thyronine nuclear receptor with the nuclear matrix of cultured growth hormone producing rat pituitary tumor cells (GC cells). J Biol Chem 261 (1986) 2844-2852
13. Pardoll D.M., Vogelstein B., and Gefty D.S. A fixed site of DNA replication in eucaryotic cell. Cell 19 (1980) 527-536
14. American Joint Committee on Cancer. Cancer Staging Manual. 5th ed. (1997), American Joint Committee on Cancer, Philadelphia
15. Grossman H.B., Messing E., Soloway M., et al. Detection of bladder cancer using a point of careproteomic assay. JAMA 293 (2005) 810-816
16. Frimberger D., Zaak D., and Hofstetter A. Endoscopic fluorescence diagnosis and laser treatment of transitional cell carcinoma of bladder. Semin Urol Oncol 18 (2000) 264-272
17. Hudson M.A., and Herr H.W. Carcinoma in situ of the bladder. J Urol 153 (1995) 564-572
18. Lokeshwar V.B., and Soloway M.S. Current bladder tumor tests: does their prolonged utility fulfill clinical necessity?. J Urol 165 (2001) 1067-1077
19. Al Sukhun S., and Hussain M. Molecular biology of TCC. Crit Rev Oncol Haematol 47 (2003) 181-193
20. Farrow G.M. Urine cytology in the detection of bladder cancer: a critical approach. J Occup Med 32 (1990) 817-821
21. Badalament R.A., Hermansen D.K., Kimmel M., et al. The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer 60 (1987) 1423-1427
22. Brown F.M. Urine cytology: is it still the gold standard for screening?. Urol Clin North Am 27 (2000) 25-37
23. Kumar A., Kumar R., and Gupta N.P. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer. Jpn J Clin Oncol 36 (2006) 172-175
24. Miller T.E., Beausang L.A., Winchell L.F., et al. Detection of nuclear matrix protein in serum from cancer patient. Cancer Res 52 (1992) 422-427
25. Partin A.W., Getzenberg R.H., Carmichael M.J., et al. Nuclear matrix protein pattern in human benign prostatic hyperplasia and prostatic cancer. Cancer Res 53 (1993) 744-746
26. Ozer G., Altinel M., Kocak B., et al. Value of urinary NMP-22 in patients with renal cell carcinoma. Urology 60 (2002) 593-597
27. Stamfer S.D., Gennaro A., Willsey L.W., et al. Evaluation of NMP22 in the detection of TCC of bladder. J Urol 159 (1998) 394-398
28. Miyanaga N., Akaza H.I., Shikawa S., et al. Clinical evaluation of nuclear matrix protein 22 in urine as a novel marker for urothelial cancer. Eur Urol 31 (1997) 163-168
29. Landman J., Yongli C., Kavaler E., et al. Sensitivity and specificity of NMP22: telomerase and BTA in the detection of human bladder cancer. Urology 52 (1998) 398-402